Company Encyclopedia
View More
name
INNOVENT BIO
01801.HK
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), PEMAZYRE (pemigatinib), olverematinib, Cyramza (ramucirumab), Retsevmo (selpercatinib), FUCASO (Equecabtagene Autoleucel), SINTBILO (tafolecimab injection), Dupert (fulzerasib), DOVBLERON (taletrectinib), Jaypirca (pirtobrutinib), limertinib, and SYCUME (teprotumumab N01 injection). The company is also developing three new drugs, which are under regulatory review; four assets in Phase 3 and pivotal clinical trials; and 15 molecules in early clinical stage.
1.240 T
01801.HKMarket value -Rank by Market Cap -/-

Financial Score

29/12/2025 Update
B
BiotechnologyIndustry
Industry Ranking2/53
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE8.43%B
    • Profit Margin9.91%B
    • Gross Margin77.26%A
  • Growth ScoreA
    • Revenue YoY53.42%A
    • Net Profit YoY188.50%A
    • Total Assets YoY18.42%A
    • Net Assets YoY18.22%A
  • Cash ScoreA
    • Cash Flow Margin1008.80%B
    • OCF YoY53.42%A
  • Operating ScoreC
    • Turnover0.52C
  • Debt ScoreB
    • Gearing Ratio38.88%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Innovent receives NMPA approval for Tabosun colon cancer treatment

    Innovent Biologics has received approval from China's NMPA for its CTLA-4 monoclonal antibody, Tabosun, for treating colon cancer. This approval allows its use in combination with sintilimab as a neoadjuvant treatment for stage IIB-III resectable MSI-H or dMMR colon cancer. The combination therapy has shown a significant improvement in pathological complete response rates, potentially reducing the need for adjuvant chemotherapy. The approval is based on the results of the pivotal Phase III NeoShot trial, which confirmed the efficacy and safety of the treatment.

    Pharmaceutical Technology·
    HK
    01801
    -1.73%
    Pharmaceutical Technology·
    HK
    01801
    -1.73%

    Innovent Bio's Tabosun Gets China Nod as Pre-treatment for Colon Cancer

    Innovent Bio's Tabosun Gets China Nod as Pre-treatment for Colon Cancer

    marketscreener·
    HK
    01801
    -1.73%
    marketscreener·
    HK
    01801
    -1.73%

    Innovent Biologics Gains China Approval for TABOSUN and Sintilimab in Colon Cancer Neoadjuvant Therapy

    Innovent Biologics Inc. has received approval from China's National Medical Products Administration for TABOSUN® and sintilimab as neoadjuvant therapy for certain colon cancers. The approval is based on the NeoShot trial, which showed an 82% pathological complete response rate among the first 50 patients treated, with no significant safety risks compared to direct surgery.

    Reuters·
    HK
    01801
    -1.73%
    Reuters·
    HK
    01801
    -1.73%

    China Greenlights World’s First Dual-Immunotherapy for Colon Cancer Ahead of Surgery

    China's drug regulator has approved Innovent Biologics' Daboxin® (Ipilimumab N01 Injection) for use with another monoclonal antibody as a pre-surgery immunotherapy for colon cancer. This is the world's first approved dual-immunotherapy neoadjuvant regimen for resectable stage IIB to III MSI-H/dMMR colon cancer. The treatment aims to improve outcomes and reduce chemotherapy reliance for patients less responsive to traditional treatments.

    Yicai·
    HK
    01801
    -1.73%
    Yicai·
    HK
    01801
    -1.73%

    Innovent Biologics Wins NMPA Approval for First Domestic CTLA-4 Antibody TABOSUN in Colon Cancer

    Innovent Biologics Inc. has received approval from China's NMPA for TABOSUN® (ipilimumab N01 injection), the first domestic CTLA-4 monoclonal antibody, for use with TYVYT® in treating stage IIB-III MSI-H/dMMR colon cancer. This marks the first global approval for such a neoadjuvant treatment, addressing a significant unmet need in China.

    Reuters·
    HK
    01801
    -1.73%
    Reuters·
    HK
    01801
    -1.73%
    Posts
    View More
    © 2025 Longbridge｜Disclaimer